BUSINESSBLOOMBERG
Shionogi-Backed Apnimed Seeks to Raise $160 Million in US IPO
Apnimed Inc., a late-stage drug developer focused on sleep apnea, is seeking to raise as much as $160 million in a US initial public offering. The company is backed by Shionogi.
Related Signal
Adjacent reporting
- Novo-Backed Drugmaker Avalyn Raises $300 Million in Upsized IPO
- Novo-Backed Drugmaker Avalyn Soars 44% After $300 Million US IPO
- Cancer drug startup Parabilis Medicines is raising a record $670 million in its IPO
- Medical Device Maker Mobia Seeks to Raise $160 Million in US IPO
- Drugmaker Parabilis Raises $745 Million in US IPO, Placement